This article is all about the affects of the 13-valent pneumococcal conjugate vaccination on virus-associated community-acquired pneumonia among elderly where in the chances of acquiring pneumonia with the vaccination is tested. The objective of this study is evaluate where this vaccination may or may not prevent the incidence of virus-associated community-acquired pnuemonia. Therefore, I have chosen this article to support or rather provide additional information about my patient’s case. My patient was diagnosed with community-acquired pneumonia status post pulmonary tuberculosis so this study may prevent further events of community-acquired pneumonia if proven effective.
The current study that was used a pre-specified exploratory objective of the Community-Acquired Pneumonia immunization Trial in Adults in which 84,496 community-dwelling individuals of 65 years and older were randomly assigned to receive PCV13 or placebo vaccination. After receiving PCV13 or placebo, participant who had any suspicisions of pneumonia were evaluated with a serious of test if they were present with any of the 12 human viruses. Through this process, the participants who were suspected and already went through various tests were divided into two groups: ‘confirmed CAP’ and ‘suspected pneumonia’. ‘Confirmed CAP’ participants underwent a chest x-ray to confirm pneumonia and if they manifested any coughing, purulent sputum, …show more content…
The majority of the ‘suspected pneumonia’ and ‘confirmed CAP’ were positive for influenza virus. After 14 days of evaluation of the ‘confirmed CAP’ individuals, 58 individuals manifested symptoms which 23 received the PCV13 and 35 received the placebo vaccine. This resulted to 34.4% efficacy of the
The current study that was used a pre-specified exploratory objective of the Community-Acquired Pneumonia immunization Trial in Adults in which 84,496 community-dwelling individuals of 65 years and older were randomly assigned to receive PCV13 or placebo vaccination. After receiving PCV13 or placebo, participant who had any suspicisions of pneumonia were evaluated with a serious of test if they were present with any of the 12 human viruses. Through this process, the participants who were suspected and already went through various tests were divided into two groups: ‘confirmed CAP’ and ‘suspected pneumonia’. ‘Confirmed CAP’ participants underwent a chest x-ray to confirm pneumonia and if they manifested any coughing, purulent sputum, …show more content…
The majority of the ‘suspected pneumonia’ and ‘confirmed CAP’ were positive for influenza virus. After 14 days of evaluation of the ‘confirmed CAP’ individuals, 58 individuals manifested symptoms which 23 received the PCV13 and 35 received the placebo vaccine. This resulted to 34.4% efficacy of the